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Introduction: Despite improvements in the treatment of advanced non-small cell lung
cancer (NSCLC), certain patient populations remain underrepresented in clinical trials.
Many patients have beneﬁted from platinum doublets, including nab-paclitaxel–based
regimens, but there are patients with comorbidities who particularly require careful
balancing of efﬁcacy and safety. Clinical trial data are limited for patients who are elderly
or have renal impairment, diabetes, or impaired performance status.
Methods: To better understand outcomes in these patient populations, we performed a
pooled analysis using data from the ABOUND clinical trial program (ABOUND.SQM,
ABOUND.PS2, ABOUND.70+) and the key phase III trial of nab-paclitaxel/carboplatin in
advanced NSCLC. The populations included in this pooled analysis consisted of elderly
patients (≥ 70 years) and patients with renal impairment (eGFR < 60 ml/min/1.73 m2),
diabetes, or poor performance status (ECOG PS 2).
Results: Median progression-free survival (PFS) ranged from 4.1 months in patients with
ECOG PS 2 (95% CI, 2.04–5.09 months) to 7.7 months in patients with diabetes (95% CI,
5.88–10.12 months). PFS for elderly patients and patients with renal impairment was 6.9
months each (95% CI, 6.01–7.98 months and 4.47–9.79 months, respectively). Median
overall survival (OS) was 18.2 months (95% CI, 10.94–28.22 months), 17.4 months (95%
CI, 14.59–20.14 months), and 16.1 months (95% CI, 14.09–18.50 months) in patients
with renal impairment, patients with diabetes, and elderly patients, respectively. Patients
with ECOG PS 2 exhibited the shortest median OS: 5.6 months (95% CI, 3.98–11.37
months). Overall response rates were 56.9%, 54.6%, 45.9%, and 29.4% in patients with
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diabetes, elderly patients, patients with renal impairment, and patients with ECOG PS 2,
respectively. Most treatment-related adverse events were hematologic. The most
common grade 3/4 hematologic adverse events in patients with renal impairment,
elderly patients, patients with diabetes, and patients with poor performance status
included neutropenia, anemia, and thrombocytopenia.
Conclusions: Although survival data in patients with ECOG PS 2 were notably inferior to
the other cohorts, our ﬁndings are consistent with those previously reported in the
population-speciﬁc studies of the ABOUND trials and lend additional support for the
use of nab-paclitaxel–based regimens in historically understudied and vulnerable
populations.
Keywords: chemotherapy, advanced non-small cell lung cancer, nab-Paclitaxel, platinum-based therapy,
vulnerable populations

in more vulnerable populations including the elderly and in
patients with renal impairment, diabetes, or ECOG PS 2.

INTRODUCTION
Treatment of advanced non-small cell lung cancer (NSCLC) has
greatly improved over the past 2 decades, and the recent advances
with immunotherapy in advanced NSCLC are particularly
encouraging (1, 2). However, some patient groups, including the
elderly and patients with renal impairment, diabetes, or poor
performance status, present unique treatment challenges because
of comorbid conditions, perceptions of increased toxicity, short
life expectancy, or compromised treatment efﬁcacy, and
underrepresentation in clinical trials (3–5). In addition, most
clinical trials in advanced cancers stipulate normal renal function
as an inclusion criterion, and elderly patients have historically been
either excluded from or underrepresented in clinical trials despite
accounting for the majority of lung cancer cases (6, 7).
Immunotherapy has demonstrated beneﬁt in patients with
advanced NSCLC but has not yet been fully studied in many of
these vulnerable populations (8). Although immunotherapy alone
or in combination with chemotherapy is now a standard of care in a
signiﬁcant proportion of patients with advanced NSCLC, cytotoxic
chemotherapy in the ﬁrst and subsequent lines of therapy
remains relevant.
Platinum-based combination chemotherapy, including nabpaclitaxel/carboplatin, has been shown to beneﬁt many patient
subgroups and was the recommended ﬁrst-line treatment strategy
for most patients prior to the advent of immunotherapy (9–11).
Subset analyses of a key phase III trial indicated that treatment with
nab-paclitaxel/carboplatin was associated with a clinical beneﬁt and
tolerable safety proﬁle in various advanced NSCLC populations
(12–14). The ABOUND clinical trial program assessed the role of
nab-paclitaxel–based regimens in patients with squamous histology
and also enrolled many patients who fell into these underserved
subset categories. The ABOUND.70+ and ABOUND.PS2 studies
highlighted the beneﬁt and tolerability of nab-paclitaxel/carboplatin
in elderly patients (≥ 70 years) and in patients with Eastern
Cooperative Oncology Group performance status (ECOG PS) 2,
respectively (15, 16).
The goal of this pooled analysis was to evaluate outcomes
associated with nab-paclitaxel/carboplatin treatment of NSCLC
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MATERIALS AND METHODS
This pooled analysis of ABOUND.SQM, ABOUND.PS2,
ABOUND.70+, and the phase III study by Socinski et al.
analyzed vulnerable populations with advanced NSCLC
(Supplemental Tables 1 and 2; D Spigel, Unpublished data,
2019) (15–17). Study designs, methods, dosing, and schedule
details have been previously published and are summarized in
Supplemental Table 3. Treatment arms containing nabpaclitaxel/carboplatin were pooled across these four studies
(patients from the ABOUND.SQM trial who received induction
therapy with nab-paclitaxel/carboplatin followed by maintenance
with best supportive care were excluded from this pooled analysis).
In each of these studies and at each participating site, the studies
were approved by IRB and the patients/participants provided
written informed consent to participate in the studies.
Demographics and baseline patient characteristics were
summarized in terms of frequencies or descriptive statistics for
categorical or continuous data, respectively. The Kaplan-Meier
product-limit method was used to estimate progression-free
survival (PFS) and overall survival (OS) curves for each
vulnerable population; median PFS and OS were deﬁned as the
shortest survival time in months in which estimated survival
probability was ≤ 0.5. The Brookmeyer-Crowley method was
used to estimate 95% CIs for medians. Median PFS and OS in the
vulnerable population compared with those of the overall
population of the pooled studies are presented in forest plots.
No statistical comparisons were performed due to the
heterogeneity of the pooled populations.

Population Deﬁnitions
The patients included in this pooled analysis were not restricted
to a single analytic cohort. For example, patients were placed in
the poor performance status group if they had ECOG PS 2;
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TABLE 1 | Baseline characteristics.

however, this did not exclude them from other groups, if
they qualiﬁed.
Renal Impairment: Renal impairment was deﬁned by
estimated glomerular ﬁltration rate (eGFR; ml/min/1.73 m2).
Moderate renal impairment included patients with an eGFR
from ≥ 30 to < 60 ml/min/1.73 m2. Severe renal impairment
included patients with an eGFR from ≥ 15 to < 30 ml/min/
1.73 m2.
Elderly Patients: Elderly patients were deﬁned as those 70
years of age or older. Age cutoff for elderly patients was chosen
for the ABOUND.70+ trial and the phase III trial subgroup
analysis and was maintained for this pooled analysis.
Patients With Diabetes: Patients with diabetes included those
classiﬁed at baseline by the preferred terms “type 2 diabetes
mellitus,” “diabetes mellitus,” and “glucose tolerance impaired”
within the system organ class “metabolism and nutrition disorders.”
Poor Performance Status: Poor performance status was
deﬁned as ECOG PS 2.

Characteristic

Age, median
(range), years
Age group, years,
n (%)
< 65
≥ 65
< 70
≥ 70
< 75
≥ 75
Gender, n (%)
Male
Female
Weight, median
(range), kg
Body mass index,
median (range),
kg/m2
Race, n (%)
Asian
African heritage
White
American Indian
or Alaska native
Other
Unknown
ECOG PS, n (%)
0
1
2
Histology, n (%)
Adenocarcinoma
Squamous cell
carcinoma
Non-squamous
cell carcinoma
Other
Unknown
Stage, n (%)
I
II
IIIA
IIIB
IV
Unknown
Prior therapy,
n (%)
Radiotherapy
Chemotherapy
Radiotherapy and
chemotherapy
Unknown
Smoking status,
n (%)
Never smoked
Quit smoking
Currently smoking
Unknown
Country, n (%)
Australia
Canada

RESULTS
Patients
A total of 840 patients in this pooled population were analyzed.
Of these, 66 (7.9%) had moderate or severe renal impairment,
293 (34.9%) were ≥ 70 years of age, 110 (13.1%) had a diagnosis
of diabetes (including 7 patients classiﬁed as glucose tolerance
impaired), and 42 (5.0%) had ECOG PS 2. Baseline
characteristics were generally similar across these patient
populations although weight and body mass index were
highest in patients with diabetes and renal impairment (Table
1). The median age for each population ranged from 66.0 to 74.0
years. Patients were predominantly male, although gender was
more evenly balanced among patients with renal impairment.
Smoking status was similar across most populations, although
patients with renal impairment included the highest proportion
of never smokers (15.2%).
Overall, the treatment discontinuation rate was 97% among
patients with renal impairment, patients aged ≥ 70 years, and
patients with diabetes and 100% among patients with ECOG PS
2. Patients with ECOG PS 2 had a lower rate of discontinuation
due to progressive disease (31.0% vs 39.3% to 43.9% in the other
populations) but higher rates of discontinuation due to death
(7.1% vs 1.5% to 3.1%), adverse events (33.3% vs 15.9% to
17.1%), and symptomatic deterioration (11.9% vs 3.0% to
6.3%) compared with patients in the other cohorts.

Efﬁcacy
Progression-Free Survival
Patients with diabetes had the longest median PFS (7.7 months;
95% CI, 5.88–10.12 months), followed by elderly patients (6.9
months; 95% CI, 6.01–7.98 months) and patients with renal
impairment (6.9 months; 95% CI, 4.47–9.79) (Figures 1A, B).
Patients with ECOG PS 2 demonstrated the shortest median PFS
(4.1 months; 95% CI, 2.04–5.09 months).
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Renal
Impairment
(n = 66)

Elderly
(n = 293)

Diabetesa
(n = 110)

Poor PS
(n = 42)

72.5
(45.0-85.0)

74.0
(70.0–93.0)

71.0
(50.0–89.0)

66.0
(44.0–84.0)

16 (24.2)
50 (75.8)
23 (34.8)
43 (65.2)
39 (59.1)
27 (40.9)

0
293 (100.0)
0
293 (100.0)
148 (50.5)
145 (49.5)

30 (27.3)
80 (72.7)
49 (44.5)
61 (55.5)
75 (68.2)
35 (31.8)

19 (45.2)
23 (54.8)
24 (57.1)
18 (42.9)
31 (73.8)
11 (26.2)

32 (48.5)
34 (51.5)
76.3
(36.2–120.2)
27.6
(17.5–47.0)

184 (62.8)
109 (37.2)
69.0b
(36.2–117.2)
24.9c
(16.0–40.5)

78 (70.9)
32 (29.1)
80.0
(46.0–124.7)
27.7
(17.6–41.5)

26 (61.9)
16 (38.1)
70.1
(42.9–111.1)
24.4
(15.7–41.5)

1 (1.5)
6 (9.1)
58 (87.9)
0

18 (6.1)
16 (5.5)
249 (85.0)
2 (0.7)

12 (10.9)
10 (9.1)
86 (78.2)
0

0
3 (7.1)
39 (92.9)
0

1 (1.5)
0

3 (1.0)
5 (1.7)

0
2 (1.8)

0
0

18 (27.3)
42 (63.6)
6 (9.1)

86 (29.4)
189 (64.5)
18 (6.1)

30 (27.3)
67 (60.9)
13 (11.8)

0
0
42 (100.0)

17 (25.8)
14 (21.2)

33 (11.3)
99 (33.8)

21 (19.1)
24 (21.8)

1 (2.4)
14 (33.3)

23 (34.8)

98 (33.4)

36 (32.7)

25 (59.5)

3 (4.5)
9 (13.6)

6 (2.0)
57 (19.5)

1 (0.9)
28 (25.5)

1 (2.4)
1 (2.4)

1 (1.5)
0
2 (3.0)
2 (3.0)
60 (90.9)
1 (1.5)

1 (0.3)
3 (1.0)
12 (4.1)
37 (12.6)
236 (80.5)
4 (1.4)

2 (1.8)
2 (1.8)
5 (4.5)
15 (13.6)
86 (78.2)
0

0
0
0
2 (4.8)
40 (95.2)
0

10 (15.2)
0
0

49 (16.7)
2 (0.7)
3 (1.0)

23 (20.9)
3 (2.7)
1 (0.9)

12 (28.6)
0
0

56 (84.8)

239 (81.6)

83 (75.5)

30 (71.4)

10 (15.2)
11 (16.7)
7 (10.6)
38 (57.6)

18 (6.1)
35 (11.9)
21 (7.2)
219 (74.7)

6 (5.5)
21 (19.1)
4 (3.6)
79 (71.8)

0
1 (2.4)
2 (4.8)
39 (92.9)

0
2 (3.0)

1 (0.3)
4 (1.4)

0
1 (0.9)

0
1 (2.4)
(Continued)
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TABLE 1 | Continued
Characteristic

a

Renal
Impairment
(n = 66)

Elderly
(n = 293)

Diabetes
(n = 110)

Poor PS
(n = 42)

2 (3.0)
0
1 (1.5)
11 (16.7)
1 (1.5)
6 (9.1)
43 (65.2)

7 (2.4)
3 (1.0)
15 (5.1)
17 (5.8)
3 (1.0)
13 (4.4)
230 (78.5)

6 (5.5)
0
9 (8.2)
9 (8.2)
3 (2.7)
1 (0.9)
81 (73.6)

0
0
0
0
0
0
41 (97.6)

7 (10.6)
59 (89.4)

37 (12.6)
256 (87.4)

59 (53.6)
51 (46.4)

7 (16.7)
35 (83.3)

49 (74.2)

233 (79.5)

71 (64.5)

4 (9.5)

10 (15.2)
0
7 (10.6)

35 (11.9)
2 (0.7)
23 (7.8)

21 (19.1)
1 (0.9)
17 (15.5)

0
0
38 (90.5)

65 (98.5)

42 (14.3)

14 (12.7)

6 (14.3)

1 (1.5)

1 (0.3)

0

0

Germany
Italy
Japan
Russia
Spain
Ukraine
United States
Metformin
therapy, n (%)
Yes
No
Peripheral
neuropathy at
baseline, n (%)
No peripheral
neuropathy
Grade 1
Grade 2
Unknown
Renal impairment,
eGFR ml/min/1.73
m2, n (%)
Moderate (eGFR
≥ 30–< 60)
Severe (eGFR ≥
15–< 30)

72.15%) and elderly patients (60.3%; 95% CI, 54.15%–65.84%).
Patients with ECOG PS 2 had the lowest rate of survival at 1-year
(28.4%; 95% CI, 14.73%–43.78%). The 2-year OS rates were
highest in patients with renal impairment (36.2%; 95% CI,
22.00%–50.57%), followed by patients with diabetes (34.0%;
95% CI, 23.53%–44.66%) and elderly patients (31.8%; 95% CI,
25.40%–38.31%). No patients with an ECOG PS 2 survived to
2 years.
Further comparative survival analyses were performed on
speciﬁc populations. The median OS was numerically longer in
patients with (n = 66) vs without (n = 774) renal impairment
(18.2 months [95% CI, 10.94–28.22 months] vs 13.0 months
[95% CI, 12.22–14.55 months]; Supplemental Figure 2A). A
longer median OS was observed in patients aged ≥ 70 years (n =
293) than in those under 70 years old (n = 547) (16.1 months
[95% CI, 14.09–18.50 months] vs 12.4 months [95% CI, 11.17–
13.73 months]; Supplemental Figure 2B). The median OS was
also longer in patients with diabetes (n = 110) than in those
without diabetes (n = 730) (17.4 months [95% CI, 14.59–20.14
months] vs 12.6 months [95% CI, 11.63–14.39 months];
Supplemental Figure 2C). However, the median OS was
numerically shorter in patients with diabetes who received
metformin (n = 59) (15.2 months [95% CI, 13.14–19.52
months]) vs those who did not (n = 51) (19.9 months [95%
CI, 16.30–28.22 months]) (Supplemental Figure 2D).

Overall Response

ECOG PS, Eastern Oncology Cooperative Group performance status; eGFR, estimated
glomerular ﬁltration rate. a Includes seven patients classiﬁed as “glucose tolerance
impaired.” b For weight of elderly population, n = 292. c For body mass index of elderly
population, n = 291.

Assessment of best overall response (by investigator in all studies
except for the phase III trial by Socinski et al, which was
performed by an independent radiology review committee)
revealed that patients with diabetes exhibited the highest
response rate [overall response rate (ORR): 56.9%; disease
control rate (DCR): 88.2%], followed by elderly patients (ORR:
54.6%; DCR: 87.8%) and patients with renal impairment (ORR:
45.9%; DCR: 82.0%). Patients with ECOG PS 2 had the lowest
response rate (ORR: 29.4%; DCR: 85.3%) (Figure 3).

Designated subsets of the pooled populations underwent further
comparative PFS analyses. No meaningful difference in median PFS
was observed in patients with (n = 66) vs without (n = 774) renal
impairment (6.9 months [95% CI, 4.47–9.79 months] vs 6.2 months
[95% CI, 5.62–6.77 months]; Supplemental Figure 1A). The
median PFS was similar in patients aged ≥ 70 years (n = 293) vs
those aged < 70 years (n = 547) (6.9 months [95% CI, 6.01–7.98
months] vs 5.7 months [95% CI, 5.49–6.67 months]; Supplemental
Figure 1B). No meaningful difference in median PFS was noted
between patients with diabetes (n = 110) and those without diabetes
(n = 730) (7.7 months [95% CI, 5.88–10.12 months] vs 6.0 months
[95% CI, 5.55–6.57]; Supplemental Figure 1C) or in patients with
diabetes who received metformin (n = 59) vs those who did not (n =
51) (6.8 months [95% CI, 4.40–10.38 months] vs 8.4 months [95%
CI, 6.83–10.15 months]; Supplemental Figure 1D).

Treatment Exposure
Across populations, the median relative dose intensity
(percentage of planned dose received) for nab-paclitaxel was
72.4% to 79.9% (Table 2). The median number of treatment
cycles ranged from 4.0 to 6.0. Dose modiﬁcations, including
reductions, interruptions, and delays, are described in Table 2.

Safety
For patients with renal impairment, elderly patients, patients
with diabetes, and patients with ECOG PS 2, treatment-related
treatment emergent adverse event (TEAE) rates were 56.1%,
71.8%, 67.3%, and 85.7%, respectively; speciﬁcally for serious
events, the rates were 10.6%, 13.2%, 13.1%, and 31.0%,
respectively. The pooled analysis showed most treatmentrelated adverse events were hematologic in nature (Table 3).
For patients with renal impairment, elderly patients, patients
with diabetes, and patients with ECOG PS 2, grade 3/4
treatment-related hematologic adverse events included
neutropenia (27.3%, 30.7%, 28.0%, and 16.7%, respectively),
anemia (15.2%, 13.6%, 13.1%, and 16.7%, respectively), and

Overall Survival
Overall, the longest median OS was observed in patients with
renal impairment (18.2 months; 95% CI, 10.94–28.22 months),
followed by patients with diabetes (17.4 months; 95% CI, 14.59–
20.14 months) and by elderly patients (16.1 months; 95% CI,
14.09–18.50 months) (Figures 2A, B). Patients with ECOG PS 2
had the shortest median OS (5.6 months; 95% CI, 3.98–11.37
months). The corresponding 1-year OS rates were highest in
patients with diabetes (71.1%; 95% CI, 61.11%–78.99%), followed
by patients with renal impairment (61.3%; 95% CI, 47.95%–

Frontiers in Oncology | www.frontiersin.org
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A

B

FIGURE 1 | Kaplan-Meier curve (A) and forest plot (B) of PFS by population. PFS, progression-free survival; PS, performance status; LCL, lower conﬁdence limit;
UCL, upper conﬁdence limit.

disorders [one event each in the renal impairment (pulmonary
embolism) and elderly (acute respiratory failure) populations].

thrombocytopenia (9.1%, 9.4%, 8.4%, and 4.8%, respectively).
Additional adverse events of interest are shown in Table 3. Of
note, grade 3/4 peripheral neuropathy was most common in
patients with diabetes (18.7%), followed by elderly patients
(12.9%), patients with renal impairment (7.6%), and patients with
ECOG PS 2 (2.4%). Also noteworthy was a single occurrence of
grade 3/4 acute kidney injury among patients with renal
impairment. Grade 5 TEAEs were mainly cardiac in nature;
elderly patients, patients with ECOG PS 2, and patients with
diabetes experienced four (cardiac arrest, 2; cardiorespiratory
arrest, 1; myocardial infarction, 1), three (cardiac arrest, 2;
arrythmia, 1), and one (myocardial infarction) events,
respectively. Additional grade 5 TEAEs were related to infections
[two events in the elderly population (pneumonia, 1; sepsis, 1)],
general disorders [one event each in the diabetes (disease
progression) and elderly (death) populations], renal and urinary
disorders [one event each (renal failure) in the renal impairment
and elderly populations], and respiratory, thoracic, and mediastinal

Frontiers in Oncology | www.frontiersin.org

DISCUSSION
Overall, the efﬁcacy and safety results of this pooled analysis
demonstrate that nab-paclitaxel–based regimens are reasonably
well tolerated and may beneﬁt patients with advanced NSCLC
who are elderly (≥ 70 years) or have diabetes, renal impairment
(eGFR < 60 ml/min/1.73 m2), or poor performance status
(ECOG PS 2). Based on their efﬁcacy and toxicity proﬁles, to
date, nab-paclitaxel–based regimens are broadly applicable to the
general NSCLC population and have been used as a platform for
the development of new immunotherapy/chemotherapy
combinations (18, 19). Patients with poor PS may fare worse,
potentially due to premature treatment discontinuation (as
supported by the higher rates of treatment discontinuation due
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A

B

FIGURE 2 | Kaplan-Meier curve (A) and forest plot (B) of OS by population. OS, overall survival; PS, performance status; LCL, lower conﬁdence limit; UCL, upper
conﬁdence limit.

renal impairment. The current pooled analysis revealed 1 grade 3/4
acute kidney injury and 1 grade 5 renal event in patients with renal
impairment. Further, patients with renal impairment unexpectedly
demonstrated longer median OS than those without impairment
(18.2 vs 13.0 months). This likely reﬂects the imbalance in patient
numbers, which included only 66 patients with vs 774 patients
without renal impairment, thereby resulting in a wide 95% CI for
the renal impairment cohort and crossing of the survival curves.
In elderly patients, including those with ECOG PS 2, taxanebased chemotherapy doublets have demonstrated signiﬁcantly
longer PFS than vinorelbine or gemcitabine monotherapy
(median PFS, 6.0 vs 2.8 months; P < 0.001) albeit with more
frequent toxicity (23). Furthermore, the subgroup analysis of
elderly patients enrolled in the pivotal phase III study
demonstrated signiﬁcantly longer median OS in those treated
with nab-paclitaxel/carboplatin (19.9 months) compared with
solvent-based paclitaxel/carboplatin (10.4 months; P = 0.009)
(14, 17). The current analysis demonstrated numerically longer
median OS in elderly patients than in patients < 70 years old,
which suggests that nab-paclitaxel is a suitable combination

to death, adverse events, or symptomatic deterioration in this
population relative to the others in our analysis), but still stand to
derive some beneﬁt from this strategy.
Deﬁning overall ﬁtness of patients with advanced NSCLC and
the inﬂuence of speciﬁc factors on suitability for chemotherapy,
as they relate to types of chemotherapy or the option to withhold
chemotherapy altogether, has been an ongoing area of interest
for facilitating clinical practice decisions (20). Generally, there
are few absolute restrictions that preclude chemotherapy
(including those based on age or renal function), except for
patients with poor PS, for whom the use of combination and in
some cases single-agent regimens should be limited.
Carboplatin is an appropriate platinum backbone for patients
with insufﬁcient renal function, as cisplatin-based chemotherapy
has been associated with severe nephrotoxicity as well as other
toxicities including greater nausea and vomiting, ototoxicity, and
neuropathy (21, 22). Further, nab-paclitaxel is predominantly
eliminated via fecal rather than renal excretion (12). Collectively,
these properties suggest that, when used together, nab-paclitaxel
and carboplatin is a reasonable treatment option for patients with
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FIGURE 3 | Response rate by population. CR, complete response; DCR, disease control rate; NE, not evaluable; ORR, overall response rate; PD, progressive
disease; PR, partial response; PS, performance status; SD, stable disease. Based on patients with baseline and at least one post baseline tumor assessment.

TABLE 2 | Treatment exposure and dose modiﬁcation.
Parameter
Treatment Exposure
No. of cycles, median (range)
Patients who received ≤ 6 cycles, n (%)
Dose intensity, median (range)
Carboplatin, mg•min/ml/wk
nab-Paclitaxel, mg/m2/wk
Relative dose intensity, median (range), %
Carboplatin
nab-Paclitaxel
Cumulative dose, median (range)
Carboplatin, mg•min/ml
nab-Paclitaxel, mg/m2

Renal Impairment (n = 66)

Elderly (n = 287)

Diabetes (n = 107)

Poor PS (n = 42)

5.0 (1.0–26.0)
48 (72.7)

6.0 (1.0–48.0)
198 (69.0)

6.0 (1.0–34.0)
64 (59.8)

4.0 (1.0–18.0)
32 (76.2)

1.9 (0.2–201.7)
66.3 (26.7–102.4)

1.4 (0.1–226.9)
62.2 (14.5–116.7)

1.4 (0.3–255.6)
63.6 (14.5–100.8)

1.4 (0.4–226.0)
55.1 (31.4–100.0)

87.6 (19.6–116.7)
76.9 (26.7–102.4)

82.5 (19.6–400.0)
72.4 (19.3–155.6)

83.2 (21.6–125.0)
74.1 (19.3–105.2)

83.8 (21.6–110.3)
79.9 (47.1–100.0)

30.0
(5.0–14252.0)
1037.5
(100.0–5150.0)

24.0
(5.0–7974.0)
1200.0
(100.0–9550.0)

24.0
(5.0–9466.0)
1300.0
(100.0–6675.0)

19.5
(5.0–1840.0)
600.0
(100.0–3200.0)

43 (65.2)
43 (65.2)

189 (65.9)
200 (69.7)

65 (60.7)
69 (64.5)

13 (31.0)
15 (35.7)

0
0

0
1 (0.3)

2 (1.9)
2 (1.9)

0
0

55 (83.3)
64 (97.0)

215 (74.9)
245 (85.4)

79 (73.8)
93 (86.9)

16 (38.1)
20 (47.6)

Dose Modiﬁcation
Patients with ≥ 1 dose reduction, n (%)
Carboplatin
nab-Paclitaxel
Patients with ≥ 1 dose interruption, n (%)
Carboplatin
nab-Paclitaxel
Patients with ≥ 1 dose delay, n (%)
Carboplatin
nab-Paclitaxel
ECOG PS, Eastern Cooperative Oncology Group performance status.

partner in this older, vulnerable population. The data presented
here, as well as data reported elsewhere, support the notion that
cytotoxic chemotherapy doublets are efﬁcacious and feasible for
elderly patients.
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TABLE 3 | Treatment-related TEAEs (≥ 5%) and other AEs of interest.
Grade 3/4 Adverse
Event, n (%)

Renal
Impairment
(n = 66)

Treatment-Related TEAEs
Neutropenia
18 (27.3)
Anemia
10 (15.2)
Leukopenia
6 (9.1)
Thrombocytopenia
6 (9.1)
Fatigue
5 (7.6)
Neutrophil count
1 (1.5)
decreased
Pneumonia
1 (1.5)
Asthenia
2 (3.0)
AEs of Interest
5 (7.6)
Peripheral neuropathya,b
7 (10.6)
Infections and
infestationsa,c
Febrile neutropenia
1 (1.5)
0
Myalgia and arthralgiaa,d

Elderly
(n = 287)

Diabetes
(n = 107)

presence of comorbidities poses a greater concern for these
patients—for example, in the current analysis, 14% of patients
with an ECOG PS 2 had moderate renal impairment at baseline,
which is concerning given their age compared with other
populations. Further studies are warranted to identify the reasons
for such poor outcomes, which should include identiﬁcation of
predictive or prognostic biomarkers that may offer potential targets
for therapeutic intervention.
The results from this pooled analysis contribute to our
understanding of the role of combination chemotherapies in
underrepresented patient populations, which historically have
presented unique treatment challenges. Overarching themes
spanning these populations include a lack of speciﬁc evidence
from treatment experiences and the assumption that treatment
may be associated with much worse toxicities due to
comorbidities. The paucity of evidence has led to a lack of
speciﬁc treatment recommendations in these patient
populations. Thus, treatment decisions may be based on
extrapolations from other trials or from prior experience.
Perception of heightened toxicity may lead to undertreatment
or, in some cases, to no treatment at all in patients who might
otherwise beneﬁt. The data presented here provide additional
support for the role of nab-paclitaxel–based treatment regimens
in elderly patients as well as patients with renal impairment,
diabetes, and ECOG PS 2.
Our study has limitations, which must be taken into
consideration when examining the data. For example, the
pooled analysis vs a randomized clinical trial in a dedicated
population does not account for differences in dosing schedules
and treatment regimens between trials. In addition, some
populations, such as those with ECOG PS 2, included a
relatively small number of patients; this is not surprising, as
most of the studies excluded patients with ECOG PS > 1. While
our analysis was designed to focus on populations that tend to be
poorly represented in clinical trials, it is possible that the resultant
small sample sizes may have inﬂuenced the unexpectedly
favorable survival results. Furthermore, the patients included in
this pooled analysis were not restricted to a single analytic cohort;
therefore, it is important to keep in mind when considering
outcomes that patients may have had additional comorbidities
beyond those highlighted in the speciﬁc comparison.
nab-Paclitaxel–based regimens are effective in populations
frequently underrepresented in clinical trials, including elderly
patients and patients with renal impairment, diabetes, and poor
performance status. In addition, there does not appear to be an
obvious exacerbation of toxicity in these populations. These results
support the role of nab-paclitaxel–based chemotherapy regimens as
a standard of care in a variety of patient populations, including those
heretofore underserved in clinical trials, and make this regimen
appealing as a platform for the development of immunotherapy.

Poor PS
(n = 42)

88 (30.7)
39 (13.6)
27 (9.4)
27 (9.4)
24 (8.4)
20 (7.0)

30 (28.0)
14 (13.1)
10 (9.3)
9 (8.4)
6 (5.6)
2 (1.9)

7 (16.7)
7 (16.7)
3 (7.1)
2 (4.8)
2 (4.8)
0

5 (1.7)
4 (1.4)

2 (1.9)
1 (0.9)

3 (7.1)
3 (7.1)

37 (12.9)
25 (8.7)

20 (18.7)
8 (7.5)

1 (2.4)
9 (21.4)

6 (2.1)
2 (0.7)

2 (1.9)
1 (0.9)

3 (7.1)
0

AE, adverse event; PS, performance status; TEAE, treatment-emergent adverse event.
a
Reported as a grouped term. bPeripheral neuropathy grouped term includes peripheral
sensory neuropathy, neuropathy peripheral, muscular weakness, peripheral motor
neuropathy, paresthesia, gait disturbance, hypoesthesia, peripheral sensorimotor
neuropathy, areﬂexia, burning sensation, peroneal nerve palsy, polyneuropathy, and
muscle atrophy. cInfections and infestations grouped term includes biliary sepsis,
cellulitis, device-related infection, diarrhea infectious, diverticulitis, infective exacerbation
of chronic obstructive airways disease, esophageal candidiasis, oral candidiasis,
osteomyelitis, pneumonia, pneumonia streptococcal, sepsis, Serratia infection, urinary
tract infection, and wound infection (2 elderly patients [0.7%] experienced grade 5
infections/infestations [pneumonia and sepsis, 1 patient each]). dMyalgia and arthralgia
grouped term includes arthralgia and myalgia.

(24–26). However, some evidence exists for prolonged survival in
patients with diabetes compared with those without diabetes
(27). In this pooled analysis, patients with diabetes exhibited
longer median OS than those without diabetes (17.4 vs 12.6
months). The explanation for these results remains unknown.
Some studies have suggested an association between metformin
treatment and improved outcomes in patients with diabetes and
various solid tumors (27). In our pooled analysis presented, patients
with diabetes who were treated with metformin had a shorter
median OS than those who were not treated with metformin
(15.2 vs 19.9 months). These results are consistent with the
subgroup analysis of patients with NSCLC and diabetes by Hirsh
et al. (13). Together, these results suggest that the hypothesized
beneﬁcial effect associated with metformin may not be applicable to
nab-paclitaxel treatment in patients with diabetes.
A modest survival improvement in patients with NSCLC and
ECOG PS 2 (including elderly patients) has been reported
previously in those treated with combination chemotherapy vs
single-agent regimens (median OS, 8.0 vs 6.6 months; P = 0.184)
(28). Patients in the pooled analysis with ECOG PS 2 demonstrated
a numerically lower median OS (5.6 months) than those in the
Lilenbaum study. However, in the prospective ABOUND.PS2
study, median OS was 7.7 months (15). Patients with advanced
NSCLC and ECOG PS 2 generally exhibit shorter OS than patients
with ECOG PS 0 or 1. It is noteworthy that this subgroup of patients
continues to demonstrate worse survival than the overall
population, despite the use of checkpoint inhibitors (29). The
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